Nuvation Bio is likely to double as it deepens its push to commercialize its cancer drug IBTROZI as well as other treatments, according to JPMorgan. The investment bank initiated coverage of Nuvation …
This cancer drug stock could double as its treatment hits the market, JPMorgan says
view original post